Delcath Systems, Inc.

NASDAQ (USD): Delcath Systems, Inc. (DCTH)

Last Price

12.79

Today's Change

+1.31 (11.41%)

Day's Change

11.51 - 12.98

Trading Volume

794,947

Overview

Market Cap

408 Million

Shares Outstanding

31 Million

Avg Volume

399,650

Avg Price (50 Days)

11.16

Avg Price (200 Days)

8.59

PE Ratio

-10.93

EPS

-1.17

Earnings Announcement

24-Mar-2025

Previous Close

11.48

Open

12.98

Day's Range

11.5101 - 12.98

Year Range

3.7 - 13.301

Trading Volume

794,947

Price Change Highlight

1 Day Change

11.41%

5 Day Change

4.15%

1 Month Change

5.62%

3 Month Change

53.73%

6 Month Change

58.49%

Ytd Change

1.43%

1 Year Change

219.75%

3 Year Change

80.14%

5 Year Change

-22.48%

10 Year Change

-98.65%

Max Change

-98.65%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Medical Devices

Description:

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Discussions
Be the first to like this. Showing 1 of 1 comments

k6ii

Anyone here see this stock?

2016-09-21 10:41

Post a Comment